These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 9236731)

  • 1. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
    den Boer JA
    J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
    Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
    J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up.
    Anholt GE; Aderka IM; van Balkom AJ; Smit JH; Hermesh H; de Haan E; van Oppen P
    J Affect Disord; 2011 Dec; 135(1-3):201-7. PubMed ID: 21889802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
    Carrasco JL; Hollander E; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1992 Nov; 53(11):387-91. PubMed ID: 1459968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of long-term outcome in obsessive-compulsive disorder.
    Jakubovski E; Diniz JB; Valerio C; Fossaluza V; Belotto-Silva C; Gorenstein C; Miguel E; Shavitt RG
    Depress Anxiety; 2013 Aug; 30(8):763-72. PubMed ID: 23109056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Price LH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
    Meltzer H; Bastani B; Jayathilake K; Maes M
    Neuropsychopharmacology; 1997 Jul; 17(1):1-11. PubMed ID: 9194044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder?
    Mancini C; Van Ameringen M; Farvolden P
    J Affect Disord; 2002 Feb; 68(1):59-65. PubMed ID: 11869783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.